Get the Stockscreener App
139.90
0.60%
-0.84
Abivax Adr stock is traded at $139.90, with a volume of 837.45K.
It is down -0.60% in the last 24 hours and up +42.71% over the past month.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
See More
Previous Close:
$140.74
Open:
$140.74
24h Volume:
837.45K
Relative Volume:
0.45
Market Cap:
$12.19B
Revenue:
-
Net Income/Loss:
$-386.19M
P/E Ratio:
-26.62
EPS:
-5.2547
Net Cash Flow:
$-206.27M
1W Performance:
-3.28%
1M Performance:
+42.71%
6M Performance:
+22.29%
1Y Performance:
+1,586%
1-Day Range:
$137.72
$141.00
1-Week Range:
$136.85
$147.98
52-Week Range:
$8.05
$148.83
Abivax Adr Stock (ABVX) Company Profile
Compare ABVX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABVX
Abivax Adr
|
139.90 | 12.19B | 0 | -386.19M | -206.27M | -5.2547 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Initiated | Jefferies | Buy |
| Feb-24-26 | Initiated | Wedbush | Outperform |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-06-25 | Initiated | Wolfe Research | Outperform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Jul-23-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-20-25 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-29-24 | Initiated | Laidlaw | Buy |
| May-20-24 | Initiated | BTIG Research | Buy |
| Apr-29-24 | Initiated | Guggenheim | Buy |
| Apr-29-24 | Initiated | Piper Sandler | Overweight |
| Nov-14-23 | Initiated | Leerink Partners | Outperform |
| Nov-14-23 | Initiated | Morgan Stanley | Equal-Weight |
View All
Abivax Adr Stock (ABVX) Latest News
Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross? - Yahoo Finance
3 Soaring Stocks That May Have More Upside Ahead - The Motley Fool
2X10 Forecast — Price Target — Prediction for 2027 - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Why Abivax’s Hot Rally Is Suddenly Cooling Off - TipRanks
Weekly Recap: Upsized $920M ADS offering and Obefazimod UC results - TradingView
Pictet Asset Management Holding SA Reduces Position in Abivax SA Sponsored ADR $ABVX - MarketBeat
ETFs Investing in Abivax SA Sponsored ADR Stocks - TradingView
Analysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Abivax SA Raises $760 Million in Major U.S. ADS Offering - TipRanks
Abivax Slides As Massive Stock Offering Spooks Traders - TipRanks
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Why is Abivax stock climbing today? - Investing.com UK
Nasdaq Gains Over 300 Points; Chicago PMI Falls In June - Sahm
Abivax stock surges on Phase 3 ulcerative colitis data By Investing.com - Investing.com Nigeria
Abivax Posts Positive Phase 3 Maintenance Data for Obefazimod in Refractory Ulcerative Colitis - TipRanks
Abivax Stock Slides as Phase 3 Update Disappoints - TipRanks
Abivax SA sponsored ADR (ABVX) loses 41.4% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Abivax SA Sponsored ADR Actuals & Estimates (NASDAQ:ABVX) - TradingView
The Nasdaq Biotechnology Index closed up more than 1.52%. Among its constituents, Absci surged 35.96%, Silence Therapeutics rose 26.00%, and Aardvark Therapeutics, Definium Therapeutics, Black Diamond, Personalis, and Adaptive Biotechnologies gai - Bitget
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), Icon (ICLR) and Liquidia Technologies (LQDA) - The Globe and Mail
ABVX News | ABIVAX SA-ADR (NASDAQ:ABVX) - ChartMill
Abivax Soars As New Crohn’s Trial Ignites Hopes - TipRanks
Abivax SA Sponsored ADR (ABVX) Gets a Buy from Guggenheim - The Globe and Mail
Barclays Keeps Their Buy Rating on Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Why Abivax SA Sponsored ADR Stock Is Sinking - TipRanks
Why Abivax Shares Are Sinking Despite Trial Success - TipRanks
ABIVAX SA-ADR (ABVX) Stock Chart - ChartMill
Analysts Have Conflicting Sentiments on These Healthcare Companies: Abivax SA Sponsored ADR (ABVX), Bausch Health Companies (BHC) and Healthequity (HQY) - The Globe and Mail
Abivax SA Sponsored ADR (ABVX) Loses 41.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Why Abivax SA Sponsored ADR Shares Are Sinking - TipRanks
Why This Biotech Plummeted Despite Its 'Best-Case' Study - Investor's Business Daily
Truist cuts Abivax stock price target on malignancy concerns By Investing.com - Investing.com Australia
Abivax shares sink as rare malignancy events cloud strong colitis trial data - Investing.com UK
Why Abivax SA Sponsored ADR Shares Are Sliding - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Biohaven Ltd. (BHVN), Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
What makes Abivax SA sponsored ADR (ABVX) a strong momentum stock: Buy now? - MSN
ABVX Technical Analysis | Trend, Signals & Chart Patterns | ABIVAX SA-ADR (NASDAQ:ABVX) - ChartMill
ABVX Q4 2025 Earnings: Wider-Than-Expected Loss Highlights Clinical-Stage Biotech ChallengesWeak Earnings Momentum - The Legal Advocate
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX) and TG Therapeutics (TGTX) - The Globe and Mail
What Makes Abivax SA Sponsored ADR (ABVX) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Abivax SA Sponsored ADR (ABVX) Gets a Buy from Barclays - The Globe and Mail
ABVXAbivax ADR Stock Price and Quote - Finviz
Abivax Adr Stock (ABVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):